Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.940
+0.150 (8.38%)
At close: Aug 13, 2025, 4:00 PM
1.920
-0.020 (-1.03%)
After-hours: Aug 13, 2025, 7:03 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$881,990
Profits / Employee
-$316,079
Market Cap
388.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ESPR News
- 6 days ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 22 days ago - Esperion to Report Second Quarter 2025 Financial Results on August 5 - GlobeNewsWire
- 6 weeks ago - Esperion Appoints Craig Thompson to Board of Directors - GlobeNewsWire
- 2 months ago - Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics? - Seeking Alpha
- 3 months ago - Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 - GlobeNewsWire
- 3 months ago - Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference - GlobeNewsWire